Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Athenagen and Zapaq merge to form neurological presence

Executive Summary

Private biotechs Athenagen (small-molecule nicotinic acetylcholine (nACh) receptor modulators) and Zapaq (founded in 2001; aspartic protease inhibitors for Alzheimer's disease) have agreed to merge, keeping the Athenagen name and focusing resources on CNS disorders. The transaction is expected to close before the end of August 2006.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Intra-Biotech Deal

Related Companies